What are the management options for endometrial (uterine lining) cancer based on staging?

Endometrial Cancer Staging and Management

Primary Surgical Management

Total hysterectomy with bilateral salpingo-oophorectomy (TAH-BSO) is the cornerstone of treatment for all stages of endometrial cancer, with the extent of lymph node assessment determined by tumor grade and depth of myometrial invasion. 1, 2

Standard Surgical Approach

• Perform total extrafascial hysterectomy with bilateral salpingo-oophorectomy via open, laparoscopic, or vaginal approach 1
• Obtain peritoneal washings for cytology at the start of surgery 1, 2
• Conduct systematic inspection and palpation of the entire abdomen, biopsying all abnormal areas 1
• Perform pelvic lymphadenectomy for complete surgical staging in most cases 1, 2
• Consider selective para-aortic lymph node sampling if pelvic nodes are enlarged or suspicious 1, 2
• Add omentectomy for serous, clear cell, or carcinosarcoma histologies 1

Modified Radical Surgery for Stage II

• Perform modified radical hysterectomy (Piver type II) when macroscopic cervical involvement is confirmed preoperatively 1
• Standard radical hysterectomy provides no additional benefit over simple hysterectomy if cervical invasion is only discovered on final pathology 1

---

Stage-Specific Adjuvant Management

Stage IA (Confined to endometrium or <50% myometrial invasion)

Grade 1-2 tumors:

• Follow-up alone is standard with no adjuvant therapy required 1, 2

Grade 3 tumors:

• Vaginal brachytherapy is optional for grade 3 disease, tumors near the cervix, or those involving the entire uterine cavity 1

Stage IB (≥50% myometrial invasion)

Grade 1-2 tumors:

• Options include vaginal brachytherapy or follow-up alone 1, 2

Grade 3 tumors:

• Either external pelvic radiotherapy ± vaginal brachytherapy boost OR vaginal brachytherapy alone 1
• External beam radiation reduces pelvic recurrence but does not improve overall survival 2

Stage II (Cervical involvement)

Stage IIA (endocervical glandular involvement only):

• Postoperative vaginal brachytherapy is standard if myometrial invasion <50% and grade 1-2 1, 2
• External pelvic radiotherapy with brachytherapy boost when myometrial invasion >50% or grade 3 1

Stage IIB (cervical stromal invasion):

• Postoperative external pelvic radiotherapy with brachytherapy boost must be performed 1, 2

Stage III (Local/regional spread)

Stage IIIA (serosa/adnexa involvement or positive cytology):

• Options include postoperative pelvic radiotherapy or abdomino-pelvic radiotherapy 1, 2
• Abdomino-pelvic radiotherapy is standard when multiple extrauterine sites are involved 1

Stage IIIB (vaginal involvement):

• Pelvic external beam irradiation with brachytherapy is standard 1, 2

Stage IIIC (pelvic lymph node metastases):

• Postoperative pelvic radiotherapy ± brachytherapy boost is standard 1, 2
• Extended-field radiotherapy to para-aortic nodes is optional 1

Stage IIIC (para-aortic lymph node metastases):

• Extended postoperative radiotherapy (pelvic and para-aortic) ± brachytherapy is standard 1

Stage IV (Distant metastases or bladder/bowel invasion)

Surgical approach:

• Cytoreductive surgery is standard when performance status permits, including total hysterectomy with BSO, bowel resection if feasible, and partial/total bladder resection with urinary diversion if necessary 1, 2
• Radical surgery improves overall survival in stage III-IV disease when complete cytoreduction is achievable 1

Adjuvant therapy:

• Postoperative external radiotherapy ± brachytherapy 1, 2
• Consider clinical trials of hormone therapy or chemotherapy 1

---

Systemic Chemotherapy Indications

For optimally debulked stage III-IV disease:

• Cisplatin plus doxorubicin significantly improves progression-free and overall survival compared to radiation alone 2
• Carboplatin plus paclitaxel represents an efficacious, lower-toxicity alternative 2, 3

For inoperable, recurrent, or metastatic disease:

• Medroxyprogesterone acetate is FDA-approved for adjunctive and palliative treatment 4

---

Critical Decision Points and Pitfalls

Lymphadenectomy Considerations

• Avoid routine pelvic lymphadenectomy in patients with poor performance status or when postoperative radiotherapy is already planned for high-risk features (grade 3, >50% myometrial invasion, stage II) 1
• Do not perform routine para-aortic lymphadenectomy as isolated para-aortic involvement is rare and pelvic node status is highly predictive of para-aortic involvement 1
• The combination of extended surgical staging plus adjuvant radiotherapy increases complication rates compared to simple hysterectomy plus radiotherapy 5

Poor Performance Status Patients

• Total hysterectomy plus BSO by abdominal approach is preferable to radiotherapy alone even in poor performance status patients with stage III disease 1

Ovarian Preservation

• Ovarian preservation may be considered in women <50 years with low-grade, early-stage endometrioid cancer, as it improves overall survival and decreases cardiovascular death without worsening cancer outcomes 1

Non-Endometrioid Histologies

• Serous, clear cell, undifferentiated, and carcinosarcoma histologies are high-risk regardless of stage and require aggressive combined modality therapy 6
• These histologies represent a genetically heterogeneous group with variable outcomes 1